

Docket No.: 85849DIV4(308597)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Andrew Segal et al.

Application No.: 12/666,833

Confirmation No.: 6845

Filed: September 19, 2003

Art Unit: 1648

For: LECTIN COMPOSITIONS AND
METHODS FOR MODULATING AN
IMMUNE RESPONSE TO AN ANTIGEN

Examiner: B. P. Blumel

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of any of a Final Office Action, a Notice of Allowance (37 CFR 1.97(c)) or an action that otherwise closes prosecution in the application.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in prior application numbers 10/655,083, filing date December 21, 2009, 10/666,898, filing date September 19, 2003, 10/666,886, filing date September 19, 2003, 10/645,000, filing date August 20, 2003, Patent No. 7,629,440, Indian Patent Application No. 2668/KOLNP/2007, filed on July 17, 2007 and Canadian Patent Application No. 2,496,384, filing date August 20, 2003, all relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 85849DIV4(308597).

Dated: December 19, 2011

Respectfully submitted,

Electronic signature: /Elizabeth Spar/
Elizabeth Spar

Registration No.: 45,123
EDWARDS WILDMAN PALMER LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 239-0575
Attorneys/Agents For Applicant